Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Branded generics industry 3600 synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Drug class trends
2.1.4 Application trends
2.1.5 Route of administration trends
2.1.6 Distribution channel trends
Chapter 3 Branded Generics Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence rate of chronic diseases
3.2.1.2 Rising number of expired patents
3.2.1.3 Increasing government initiatives to promote generic products
3.2.2 Industry pitfalls & challenges
3.2.2.1 Competition from standard generics and brand-name drugs
3.2.2.2 Regulatory barriers
3.3 Growth potential analysis
3.3.1 By drug class
3.3.2 By application
3.3.3 By route of administration
3.3.4 By distribution channel
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Branded Generics Market, By Drug Class, 2018 - 2032 (USD Million)
5.1 Key trends, by drug class
5.2 Anti-hypertensive
5.3 Hormones
5.4 Antimetabolites
5.5 Anti-depressants
5.6 Alkylating agents
5.7 Lipid lowering drugs
5.8 Anti-epileptics
5.9 Anti-psychotics
5.10 Other drug classes
Chapter 6 Branded Generics Market, By Application, 2018 - 2032 (USD Million)
6.1 Key trends, by application
6.2 Oncology
6.3 Cardiovascular diseases
6.4 Neurological diseases
6.5 Gastrointestinal diseases
6.6 Dermatological diseases
6.7 Acute & chronic pain
6.8 Other applications
Chapter 7 Branded Generics Market, By Route of Administration, 2018 - 2032 (USD Million)
7.1 Key trends, by route of administration
7.2 Oral
7.3 Topical
7.4 Parenteral
7.5 Other routes of administration
Chapter 8 Branded Generics Market, By Distribution Channel, 2018 - 2032 (USD Million)
8.1 Key trends, by distribution channel
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy
Chapter 9 Branded Generics Market, By Region, 2018 - 2032 (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East & Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 Teva Pharmaceutical Industries Ltd.
10.2 Lupin
10.3 Sanofi
10.4 Sun Pharmaceutical Industries, Ltd.
10.5 Dr. Reddy's Laboratories Ltd
10.6 Endo International plc
10.7 Pfizer, Inc.
10.8 Viatris, Inc.
10.9 Abbott Laboratories
10.10 Sandoz
